Evidence map›Paper›PMID 42523628›Full record

ArticlebioRxiv : the preprint server for biology2026

High Throughput Characterization of Eukaryotic 2A-Like Peptides Identifies Novel Leucine-Associated Reduction in Protein Abundance.

John C Snell, Kenneth A Matreyek

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

John C SnellDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0003-2683-6108
Kenneth A MatreyekDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0001-9149-551X

Funding

Recombinant DNA technologies for multiplex genetic assays in human cellsR35GM142886 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI MATREYEK, KENNETH A · 2021 to 2025
$2.0M
Microparticle Sorting for the Study of New ImmunotherapiesS10OD026841 · OD · CASE WESTERN RESERVE UNIVERSITY · PI GRIMBERG, BRIAN T. · 2020 to 2020
$600k
NIGMS NIH HHS R35 GM142886NIH HHS S10 OD026841
6 · The paper itself

Abstract

Virally-derived ribosomal skipping 2A peptides are a popular tool for protein co-expression. Despite their use in over 9,000 publications, the biochemical and biophysical properties underlying the skipping mechanism remain largely unexplored. We identified 4,218 2A-like peptides originating from non-viral organisms. We developed and utilized the Trifluorescent Reporter fluorescent tool for high-throughput multiplexable analysis of ribosomal skipping, and tested 3,271 2A-like peptide sequences. We identified peptides that skipped, failed to skip, and skipped but failed to restart translation, in addition to peptides that induced a reduction in protein abundance. Peptides that skipped and induced reductions in protein abundance largely originated from eukaryotes. A poly-leucine stretch in an alpha-helix N-terminal to the conserved GDxExNPGP motif drove both skipping and the reduction in protein abundance. Analysis of the native eukaryotic protein contexts revealed that reduction may be harnessed as an expression regulator. The high-throughput approach used in this work greatly expands the functional knowledge of what biophysical and biochemical characteristics lead to ribosomal skipping, including an apparent latent eukaryotic 'leucine stall-helix' motif.

Identifiers

PMID42523628
PMCPMC13405545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.